Key Highlights

  • Inovio (NASDAQ:INO) traded at USD 0.9089, up 4.50%, in pre-market trading on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day accompanied the move, which comes three days before the FDA action date.
  • For the second quarter ended June 30, 2026, the company reported a net loss of USD 6.0 million, or USD 0.07 per share, against USD 23.5 million a year earlier, aided by a USD 13.9 million non-cash warrant gain.
  • The company's release of Wednesday, August 12, 2026 stated that the FDA target action date for INO-3107 is Friday, October 30, 2026, with cash of USD 36.7 million at June 30, 2026 and funding into the late first quarter of 2027.
  • Approval is not assured, and the FDA had not discussed its preliminary comment on accelerated approval eligibility. Pre-market quotes are thinly traded and can change before the open.

The Pre-Market Move and Its Catalyst

Inovio (NASDAQ:INO), a clinical-stage company developing DNA medicines, traded at USD 0.9089, up 4.50%, in pre-market trading on Tuesday, October 27, 2026, according to a pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The most recent company release reviewed is the second quarter 2026 results release of Wednesday, August 12, 2026, which set the target action date for INO-3107, its candidate for recurrent respiratory papillomatosis, a rare disease in which benign growths form in the airway, at Friday, October 30, 2026. The gain appears consistent with positioning ahead of that regulatory date and with thin pre-market liquidity, both inferences and not reported causes.

How the Latest Results Frame the Move

Inovio reported no revenue for the second quarter ended June 30, 2026. The net loss was USD 6.0 million, or USD 0.07 per share, against USD 23.5 million, or USD 0.61 per share, a year earlier, and the narrowing reflects a USD 13.9 million non-cash gain on the fair value of warrant liabilities. Research and development expense fell to USD 10.8 million from USD 14.5 million, general and administrative expense fell to USD 7.8 million from USD 8.6 million, and total operating expenses were USD 18.6 million. Cash, cash equivalents and short-term investments were USD 36.7 million, excluding about USD 18.3 million of net proceeds from a July 2026 offering, against USD 58.5 million at December 31, 2025. The company expects funding into the late first quarter of 2027, assuming net cash burn of about USD 18 million in the third quarter.

Risks and What to Watch

The bull reading rests on completed late-cycle review and pre-licensure inspections, Orphan Drug and Breakthrough Therapy designations and commercial preparation with Syneos Health as contract sales organisation. The bear reading rests on the FDA not discussing its preliminary comment on accelerated approval eligibility, on pending feedback regarding the confirmatory trial design, and on a cash runway that ends in the late first quarter of 2027 on the company's assumptions. Named risks are regulatory delay or refusal, further dilution after the July 2026 offering and the volatility of a stock priced below USD 1.00. Investors should watch the FDA action on Friday, October 30, 2026, the Federal Reserve decision of Wednesday, October 28, 2026 and any financing announced after the decision.

Where Things Stand

The answer is that Inovio (NASDAQ:INO) can hold its 4.50% pre-market gain only if the FDA action of Friday, October 30, 2026 supports it, since no company announcement accompanied the move and the gain appears consistent with positioning. The key number is cash of USD 36.7 million at June 30, 2026, against quarterly operating expenses of USD 18.6 million. The next catalysts are the Federal Reserve decision of Wednesday, October 28, 2026, which follows the rate rise of Wednesday, September 16, 2026, and the FDA action of Friday, October 30, 2026. Pre-market prices are snapshots and can change, and this is not investment advice.